Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Designed Host Defense Peptides for the Treatment of Bacterial Keratitis.

Clemens LE, Jaynes J, Lim E, Kolar SS, Reins RY, Baidouri H, Hanlon S, McDermott AM, Woodburn KW.

Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6273-6281. doi: 10.1167/iovs.17-22243.

2.

Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats.

Kiss K, Csonka C, Pálóczi J, Pipis J, Görbe A, Kocsis GF, Murlasits Z, Sárközy M, Szűcs G, Holmes CP, Pan Y, Bhandari A, Csont T, Shamloo M, Woodburn KW, Ferdinandy P, Bencsik P.

Pharmacol Res. 2016 Nov;113(Pt A):62-70. doi: 10.1016/j.phrs.2016.08.013. Epub 2016 Aug 10.

PMID:
27521836
3.

Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration.

Woodburn KW, Fong KL, Wilson SD, Sloneker S, Strzemienski P, Solon E, Moriya Y, Tagawa Y.

Drug Metab Dispos. 2013 Apr;41(4):774-84. doi: 10.1124/dmd.112.048033. Epub 2013 Jan 14.

PMID:
23318685
4.

Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats.

Woodburn KW, Holmes CP, Wilson SD, Fong KL, Press RJ, Moriya Y, Tagawa Y.

Xenobiotica. 2012 Jul;42(7):660-70. doi: 10.3109/00498254.2011.649310. Epub 2011 Dec 22.

5.

Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice.

Woodburn KW, Schatz PJ, Wilson S, Fong KL, Wagner VO, Gudi R, Krsmanovic L, Paranjpe M, Shah SA.

Drug Chem Toxicol. 2011 Jul;34(3):240-9. doi: 10.3109/01480545.2010.510140.

PMID:
21649477
6.

Peri- and postnatal rodent development of Hematide, an erythropoiesis-stimulating agent.

Lewis EM, Hoberman AM, Fong KL, Schatz PJ, Wilson SD, Woodburn KW.

Birth Defects Res B Dev Reprod Toxicol. 2010 Apr;89(2):155-63. doi: 10.1002/bdrb.20243.

PMID:
20437475
7.

Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.

Woodburn KW, Schatz PJ, Fong KL, Beaumier P.

Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):121-9.

PMID:
20378000
8.

A subchronic murine intravenous pharmacokinetic and toxicity study of Hematide™, a PEGylated peptidic erythropoiesis-stimulating agent.

Woodburn KW, Fan Q, Schatz PJ, Wilson SD, Fong KL, Norton D.

Drug Chem Toxicol. 2010 Jan;33(1):28-37. doi: 10.3109/01480540903176610.

PMID:
19995307
9.

Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents.

Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Spainhour CB, Norton D.

Basic Clin Pharmacol Toxicol. 2009 Feb;104(2):155-63. doi: 10.1111/j.1742-7843.2008.00347.x. Epub 2008 Dec 16.

10.

Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys.

Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Ferrell T, Spainhour CB, Norton D.

Haematologica. 2008 Sep;93(9):1376-9. doi: 10.3324/haematol.12896. Epub 2008 Jun 2.

11.

Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys.

Woodburn KW, Schatz PJ, Fong KL, Wilson SD, Ferrell T, Spainhour CB, Norton D.

Drug Chem Toxicol. 2008;31(2):229-44. doi: 10.1080/01480540701873186 .

PMID:
18330784
12.

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

Woodburn KW, Fan Q, Winslow S, Chen MJ, Mortensen RB, Casadevall N, Stead RB, Schatz PJ.

Exp Hematol. 2007 Aug;35(8):1201-8.

PMID:
17662888
13.

Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.

Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW.

Exp Hematol. 2006 Oct;34(10):1303-11.

PMID:
16982323
14.

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM.

Blood. 2006 Sep 15;108(6):1830-4. Epub 2006 May 23.

15.

Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.

Chou TM, Woodburn KW, Cheong WF, Lacy SA, Sudhir K, Adelman DC, Wahr D.

Catheter Cardiovasc Interv. 2002 Nov;57(3):387-94. Review.

PMID:
12410519
16.

Post surgical pain management with poly(ortho esters).

Barr J, Woodburn KW, Ng SY, Shen HR, Heller J.

Adv Drug Deliv Rev. 2002 Oct 16;54(7):1041-8. Review.

PMID:
12384320
17.

Photodynamic therapy for choroidal neovascularization: a review.

Woodburn KW, Engelman CJ, Blumenkranz MS.

Retina. 2002 Aug;22(4):391-405; quiz 527-8. Review.

PMID:
12172104
18.

Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin.

Miller RA, Woodburn KW, Fan Q, Lee I, Miles D, Duran G, Sikic B, Magda D.

Clin Cancer Res. 2001 Oct;7(10):3215-21.

19.

Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease.

Yamaguchi A, Woodburn KW, Hayase M, Hoyt G, Robbins RC.

Transplantation. 2001 Jun 15;71(11):1526-32.

PMID:
11435960
20.

Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.

Chen Z, Woodburn KW, Shi C, Adelman DC, Rogers C, Simon DI.

Arterioscler Thromb Vasc Biol. 2001 May;21(5):759-64.

PMID:
11348871
21.
22.

Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model.

Yamaguchi A, Woodburn KW, Hayase M, Robbins RC.

Circulation. 2000 Nov 7;102(19 Suppl 3):III275-80.

PMID:
11082401
23.

Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy.

Rockson SG, Lorenz DP, Cheong WF, Woodburn KW.

Circulation. 2000 Aug 1;102(5):591-6. Review.

PMID:
10920074
24.

Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy.

Blumenkranz MS, Woodburn KW, Qing F, Verdooner S, Kessel D, Miller R.

Am J Ophthalmol. 2000 Mar;129(3):353-62.

PMID:
10704552
25.

Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin.

Woodburn KW, Fan Q, Kessel D, Luo Y, Young SW.

J Invest Dermatol. 1998 May;110(5):746-51.

26.

Localization and efficacy analysis of the phototherapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model.

Woodburn KW, Fan Q, Miles DR, Kessel D, Luo Y, Young SW.

Photochem Photobiol. 1997 Mar;65(3):410-5.

PMID:
9077121
27.

Phototherapy of cancer and atheromatous plaque with texaphyrins.

Woodburn KW, Fan Q, Kessel D, Wright M, Mody TD, Hemmi G, Magda D, Sessler JL, Dow WC, Miller RA, Young SW.

J Clin Laser Med Surg. 1996 Oct;14(5):343-8.

PMID:
9612202
28.

Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer.

Young SW, Woodburn KW, Wright M, Mody TD, Fan Q, Sessler JL, Dow WC, Miller RA.

Photochem Photobiol. 1996 Jun;63(6):892-7.

PMID:
8992510
29.

Biodistribution of haematoporphyrin analogues in a lung carcinoma model.

Tronconi M, Colombo A, De Cesare M, Marchesini R, Woodburn KW, Reiss JA, Phillips DR, Zunino F.

Cancer Lett. 1995 Jan 6;88(1):41-8.

PMID:
7850772
30.

Evaluation of a morpholinothiolporphyrin for use in photodynamic therapy.

Woodburn KW, Hill JS, Stylli S, Kaye AH, Reiss JA, Phillips DR.

Br J Cancer. 1994 Sep;70(3):398-400.

31.

Evaluation of porphyrin characteristics required for photodynamic therapy.

Woodburn KW, Vardaxis NJ, Hill JS, Kaye AH, Reiss JA, Phillips DR.

Photochem Photobiol. 1992 May;55(5):697-704.

PMID:
1528983
32.

Evaluation of tumour and tissue distribution of porphyrins for use in photodynamic therapy.

Woodburn KW, Stylli S, Hill JS, Kaye AH, Reiss JA, Phillips DR.

Br J Cancer. 1992 Mar;65(3):321-8.

33.

Subcellular localization of porphyrins using confocal laser scanning microscopy.

Woodburn KW, Vardaxis NJ, Hill JS, Kaye AH, Phillips DR.

Photochem Photobiol. 1991 Nov;54(5):725-32.

PMID:
1724698

Supplemental Content

Loading ...
Support Center